Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO 2018 | Uro-Onc data at ESMO 2018: what to look out for

Name: Uro-Onc data at ESMO 2018: what to look out for
Uploaded: 2018-10-19T00:00:00.000Z
Duration: 1 min 22 s

Alison Birtle • 19 Oct 2018

ESMO 2018

Genitourinary Cancer Prostate Cancer Abiraterone Docetaxel Pembrolizumab Radium-223 Ramucirumab

ERA 223 RANGE STAMPEDE

Data from ERA 223 (NCT02043678) and many other uro-oncology trials were released at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. We spoke to Alison Birtle, MD, of Royal Preston Hospital Lancashire Teaching Hospitals, Preston, UK, about this at the meeting. She highlights the learning points from ERA 223, which combined radium-223 and abiraterone, and discusses the upcoming data she is looking out for at ESMO 2018: pembrolizumab for BCG-refractory non-muscle invasive bladder cancer, the RANGE study of ramucirumab plus docetaxel for urothelial cancer (NCT02426125), and the STAMPEDE trial of systemic therapy for advancing or metastatic prostate cancer (NCT00268476).